Mechanism of action of Xolair (omalizumab) as treatment for hives

Registry ID

EUCTR2014-005127-27

Source registry

EUCTR

Status

Ongoing

Phase

PHASE4

Sponsor

UMC Utrecht

Start date

2015-05-27

Last update

2026-08-16

Conditions

• Chronic spontaneous urticaria

Summary

To relate the reduction of inflammatory characteristics in the skin and peripheral blood to clinical efficacy of Xolair (omalizumab) in patients with CSU.

Locations

• , , Netherlands

Related clinical trials

• Characterization of biomarkers to identify "responders" and "non-responders" in chronic spontaneous urticaria (CSU) therapy

View on source registry